Business
BMO downgrades Biogen, claims the company is spending too much on controversial Alzheimer’s drug
Biogen’s new Alzheimer’s drug had limited sales during its first few months on the market.
Source link
Biogen’s new Alzheimer’s drug had limited sales during its first few months on the market.
Source link
